Nakanishi T - Search Results

1

Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924.

Hou X, Huang F, Carboni JM, Flatten K, Asmann YW, Ten Eyck C, Nakanishi T, Tibodeau JD, Ross DD, Gottardis MM, Erlichman C, Kaufmann SH, Haluska P. Hou X, et al. Among authors: nakanishi t. Mol Cancer Ther. 2011 Jan;10(1):117-25. doi: 10.1158/1535-7163.MCT-10-0438. Mol Cancer Ther. 2011. PMID: 21220496 Free PMC article.

2

Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.

Nakanishi T, Ross DD. Nakanishi T, et al. Chin J Cancer. 2012 Feb;31(2):73-99. doi: 10.5732/cjc.011.10320. Epub 2011 Nov 18. Chin J Cancer. 2012. PMID: 22098950 Free PMC article. Review.

3

Impact of breast cancer resistance protein on cancer treatment outcomes.

Ross DD, Nakanishi T. Ross DD, et al. Among authors: nakanishi t. Methods Mol Biol. 2010;596:251-90. doi: 10.1007/978-1-60761-416-6_12. Methods Mol Biol. 2010. PMID: 19949928

4

Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients.

Nakanishi T, Karp JE, Tan M, Doyle LA, Peters T, Yang W, Wei D, Ross DD. Nakanishi T, et al. Clin Cancer Res. 2003 Aug 15;9(9):3320-8. Clin Cancer Res. 2003. PMID: 12960118

5

Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis.

Nakanishi T, Doyle LA, Hassel B, Wei Y, Bauer KS, Wu S, Pumplin DW, Fang HB, Ross DD. Nakanishi T, et al. Mol Pharmacol. 2003 Dec;64(6):1452-62. doi: 10.1124/mol.64.6.1452. Mol Pharmacol. 2003. PMID: 14645676

6

Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage.

Nakanishi T, Bailey-Dell KJ, Hassel BA, Shiozawa K, Sullivan DM, Turner J, Ross DD. Nakanishi T, et al. Cancer Res. 2006 May 15;66(10):5007-11. doi: 10.1158/0008-5472.CAN-05-4572. Cancer Res. 2006. PMID: 16707421

7

Methods to evaluate transporter activity in cancer.

Nakanishi T, Ross DD, Mitsuoka K. Nakanishi T, et al. Methods Mol Biol. 2010;637:105-20. doi: 10.1007/978-1-60761-700-6_5. Methods Mol Biol. 2010. PMID: 20419431

8

Functional cyclic AMP response element in the breast cancer resistance protein (BCRP/ABCG2) promoter modulates epidermal growth factor receptor pathway- or androgen withdrawal-mediated BCRP/ABCG2 transcription in human cancer cells.

Xie Y, Nakanishi T, Natarajan K, Safren L, Hamburger AW, Hussain A, Ross DD. Xie Y, et al. Among authors: nakanishi t. Biochim Biophys Acta. 2015 Mar;1849(3):317-27. doi: 10.1016/j.bbagrm.2015.01.003. Epub 2015 Jan 21. Biochim Biophys Acta. 2015. PMID: 25615818 Free PMC article.

9

Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression.

Nakanishi T, Shiozawa K, Hassel BA, Ross DD. Nakanishi T, et al. Blood. 2006 Jul 15;108(2):678-84. doi: 10.1182/blood-2005-10-4020. Epub 2006 Mar 16. Blood. 2006. PMID: 16543472 Free article.

10

Thapsigargin resistance in human prostate cancer cells.

O'Neill JP, Velalar CN, Lee DI, Zhang B, Nakanishi T, Tang Y, Selaru F, Ross D, Meltzer SJ, Hussain A. O'Neill JP, et al. Among authors: nakanishi t. Cancer. 2006 Aug 1;107(3):649-59. doi: 10.1002/cncr.22027. Cancer. 2006. PMID: 16770788 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,736 results

Search Page